MLYS — Mineralys Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $1.00bn
- $802.20m
- 24
- 12
- 92
- 37
Annual income statement for Mineralys Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 2.94 | 18.7 | 31.5 | 84.7 | 192 |
| Operating Profit | -2.94 | -18.7 | -31.5 | -84.7 | -192 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -3.43 | -19.4 | -29.8 | -71.9 | -178 |
| Net Income After Taxes | -3.43 | -19.4 | -29.8 | -71.9 | -178 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.43 | -19.4 | -29.8 | -71.9 | -178 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.43 | -19.4 | -29.8 | -71.9 | -178 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.092 | -0.524 | -0.804 | -1.99 | -3.66 |